Definium Therapeutics, Inc. develops investigational therapeutics for psychiatric and neurological disorders. The company’s news centers on DT120 ODT (lysergide tartrate), its lead Phase 3 program for generalized anxiety disorder and major depressive disorder, along with clinical-trial progress, pre-commercial planning, and updates on the treatment landscape for mood and anxiety disorders.
Recurring announcements also include quarterly and annual financial results, investor and analyst events, research publications related to generalized anxiety disorder, and public-company compensation actions such as Nasdaq inducement grants for new employees.
Definium Therapeutics (DFTX) issued inducement options covering 45,940 common shares to two newly hired non-executive employees, effective October 13, 2026.
The exercise price equals the common shares’ closing price on the grant date. The options vest over four years: 25% on the first grant anniversary and the remaining 75% in substantially equal monthly increments over the following three years, subject to continued employment. The Compensation Committee approved the grants on October 11, 2026, under Nasdaq Rule 5635(c)(4). The awards were granted under the company’s 2026 Inducement Plan as a material inducement to employment.
Definium Therapeutics (DFTX) granted options to purchase 334,810 common shares to newly hired non-executive employees.
The grants cover 15 employees and took effect September 28, 2026. The exercise price equals the closing share price on each grant date. The options vest over four years: 25% on the first anniversary and the remaining 75% in substantially equal monthly increments over the next three years, subject to each employee’s continued employment. The grants were made under Definium’s 2026 Inducement Plan.
Definium Therapeutics (DFTX) reported positive topline results from Panorama, its second Phase 3 trial of DT120 ODT in generalized anxiety disorder (GAD) and third positive Phase 3 readout for DT120 overall.
The study met its primary endpoint, with DT120 ODT 100 µg showing a Least Squares mean change in HAM-A total score of -9.8 at Week 12 versus -4.7 for placebo, a placebo-adjusted difference of -5.1 points (p<0.0001; Cohen’s d=0.64). All key secondary endpoints, including CGI-S change at Week 12, HAM-A change at Week 1, and CGI-S change at Day 2, also achieved statistical significance. Response and remission rates on HAM-A at Week 12 favored DT120 over placebo.
DT120 ODT 100 µg was generally well tolerated, with no drug-related serious adverse events and no suicidality signal. A pre-NDA meeting with FDA is scheduled for 4Q 2026, and an NDA filing is anticipated in 1H 2027.
Definium Therapeutics (DFTX) granted inducement stock options to three newly hired non-executive employees to purchase an aggregate of 56,650 common shares, with effective grant dates of September 14, 2026.
The options have an exercise price equal to the closing price of Definium’s common shares on the grant date. Vesting occurs over four years: 25% on the first anniversary of the grant date and the remaining 75% in substantially equal monthly installments over the following three years, subject to continued employment. The options were approved by the Compensation Committee on September 11, 2026 as material inducements to employment, in line with Rule 5635(c)(4) of The NASDAQ Stock Market LLC, and were issued under Definium’s 2026 Inducement Plan.
Definium Therapeutics (DFTX) will host a live webcast on September 14, 2026, at 8:00 a.m. EDT to discuss topline results from Panorama, its second Phase 3 study of DT120 (lysergide) Orally Disintegrating Tablet in adults with generalized anxiety disorder.
Listeners and analysts can register via provided links, with a replay available in the Investor Relations section of the company website for at least 30 days. Participants are advised to join 15 minutes before the start time.
Definium Therapeutics (DFTX) will present topline Phase 3 data from its DT120 Orally Disintegrating Tablet program in generalized anxiety disorder (GAD) and major depressive disorder (MDD) at Psych Congress 2026 in New Orleans. The company will share Phase 3 results for DT120 (lysergide) in both GAD and MDD, safety findings from Phase 1 and 2 studies, and a Phase 3 trial design and methodology poster covering treatment in both indications. Definium will also present new epidemiological research on suicidal ideation across anxiety, depression, and comorbid cohorts, as well as an analysis of number needed to treat and number needed to harm (NNT/NNH) for DT120 in MDD.
Posters are scheduled for Thursday, September 17, and Friday, September 18, from 1:15 PM to 3:30 PM CDT in the Poster Hall, with an invited oral presentation in the “Latest Discoveries & Emerging Trends in MDD” session on Thursday, September 17, from 9:00 AM to 10:00 AM CDT in Great Hall A. Definium will also host a medical affairs booth at #912 during the Congress.
Definium Therapeutics (DFTX) received U.S. FDA Breakthrough Therapy designation for DT120 (lysergide) orally disintegrating tablet in major depressive disorder, supported by positive Phase 3 data.
In the Phase 3 Emerge study, a single 100 µg dose of DT120 ODT produced a statistically significant 8.1‑point placebo‑adjusted improvement in Montgomery‑Åsberg Depression Rating Scale (MADRS) total score at Week 6 (p<0.0001), with durable efficacy maintained through Week 12. This is the second Breakthrough Therapy designation for the DT120 program, following an earlier designation in generalized anxiety disorder.
DT120 ODT is Definium’s proprietary, pharmaceutically optimized formulation of LSD using Catalent’s Zydis fast‑dissolve technology, designed for faster absorption, improved bioavailability, and potentially fewer gastrointestinal side effects. Definium is advancing DT120 ODT for MDD, GAD, posttraumatic stress disorder, and other serious brain health disorders under a multi‑layered patent strategy.
Definium Therapeutics (NASDAQ: DFTX) granted inducement stock options to three newly hired non-executive employees, covering an aggregate of 88,900 common shares, with an effective grant date of August 31, 2026. The exercise price equals the closing price of Definium’s common shares on the grant date.
According to Definium, the options vest over four years: 25% on the first anniversary and the remaining 75% in substantially equal monthly installments over the following three years, subject to continued employment. The grants were approved by the Compensation Committee on August 28, 2026 under NASDAQ Rule 5635(c)(4) and issued pursuant to the company’s 2026 Inducement Plan.
Definium Therapeutics (Nasdaq: DFTX) announced that its management will participate in several upcoming investor events. On September 1, 2026, the company will join a Stifel-hosted virtual fireside chat focused on positive topline Phase 3 Voyage results for DT120 ODT in generalized anxiety disorder (GAD) and expectations for the Phase 3 Panorama topline readout. Definium will also present at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026 and attend the Leerink Partners Biopharma Summit from September 23–25, 2026. Audio webcasts and replays of available presentations will be posted on Definium’s investor relations website for up to 90 days after each event.
Definium Therapeutics (NASDAQ: DFTX) announced that it has granted inducement equity awards to two newly hired non-executive employees. The awards consist of options to purchase an aggregate of 32,900 common shares, with an exercise price equal to the closing price of Definium’s common shares on the August 17, 2026 grant date.
The stock options will vest over four years, with 25% vesting on the first anniversary of the grant date and the remaining 75% vesting in substantially equal monthly installments over the following three years, subject to continued employment. According to the company, the options were approved by the Compensation Committee on August 14, 2026 as material inducements to employment under NASDAQ Rule 5635(c)(4) and were issued under Definium’s 2026 Inducement Plan.